Aye Finance moves to reshape its capital structure

The 12.63 lakh options granted under the ESOP 2024 plan feature a vesting schedule of one to four years and an exercise price set at 95% of the closing share price on the grant date ^[1].

ESOP 2024 Terms

• Grant Size: 12,63,280 options, approved by the Nomination and Remuneration Committee on July 20, 2026 ^[1].
• Exercise Price: 95% of the latest available closing price on the grant date. If the company's shares are listed on multiple exchanges, the price is determined by the closing price on the exchange with the higher trading volume ^[1].
• Vesting Schedule: Options vest over a period ranging from a minimum of one year to a maximum of four years from the date of grant ^[1].
• Exercise Period: Once vested, options are exercisable within a period of five years from the date of vesting ^[1].

Alignment with Previous Tranches

The company's public filings do not disclose specific exercise prices or historical vesting terms for previous ESOP tranches, preventing a direct quantitative comparison of these terms ^[2]. While the company's regulatory disclosures confirm that previous schemes allowed for vesting at definite dates and exercise at the discretion of the Board, the specific pricing methodologies or historical strike prices for earlier grants are not publicly available in the provided context ^[2].

Implications

The 95% pricing mechanism provides a modest discount to the prevailing market price, a common structure intended to incentivize employee retention while aligning participant interests with share price performance. The five-year exercise window post-vesting offers participants significant flexibility in managing their tax and liquidity requirements.

Verdict

The absolute potential dilution from the ESOP 2024 grant is capped at 12,63,280 equity shares of face value Rs 2 each ^[1]. However, the exact percentage dilution to the existing equity base and the precise incremental impact on employee benefit expenses for the current fiscal year (FY27) cannot be quantified because the company's total outstanding equity share capital and the fair valuation parameters of the options are not reported in the corporate disclosures.

From a timing perspective, because the minimum vesting period is 1 year ^[1], no actual share issuance or equity dilution will occur during the current fiscal year (FY27). The incremental employee benefit expense will begin amortizing in FY27 over the 1-to-4-year vesting period ^[1], but the exact charge remains undisclosed.

---

ESOP 2024 Grant Terms

The Nomination and Remuneration Committee approved the grant on July 20, 2026 ^[2], under the following structured terms:

• Total Options Granted: 12,63,280 options to eligible employees ^[2].
• Underlying Shares: 12,63,280 equity shares of face value Rs 2 each, where 1 option converts to 1 share ^[1].
• Exercise Price: Set at 95% of the latest available closing price on the stock exchange with the higher trading volume on the grant date ^[1].
• Vesting Schedule: Minimum of 1 year and maximum of 4 years from the grant date ^[1].
• Exercise Window: Vested options can be exercised within 5 years from the vesting date ^[1].
• Implementation Route: Direct route involving fresh allotment of shares upon exercise, which will rank pari-passu with existing shares ^[1].

---

Financial and Accounting Implications

1. Dilution Timeline

Because the options have a minimum vesting period of 1 year from the grant date of July 20, 2026 ^[2], the earliest any option can vest and be exercised is July 20, 2027 (which falls in FY28). Consequently:

• FY27 Dilution: Zero. There will be no increase in the outstanding share count or dilution of EPS in the current fiscal year.
• FY28 and Beyond: Dilution will occur gradually over a maximum of 9 years (up to 4 years vesting plus a 5-year exercise window) ^[1], depending on employee retention and exercise behavior.

2. Employee Benefit Expense Impact

Under Ind AS 102 (Share-based Payment), the company must estimate the fair value of the options on the grant date (typically using the Black-Scholes option pricing model) and amortize this cost as an employee benefit expense over the vesting period.

• Discount Pricing: Since the exercise price is set at 95% of the market price (a 5% discount) ^[1], the options will have a positive intrinsic value at grant, which increases the overall fair value and subsequent non-cash employee compensation expense.
• Amortization Period: The expense will be recognized over 1 to 4 years ^[1]. If graded vesting is applied, the expense will be heavily front-loaded into the first 12 to 24 months (spanning FY27 and FY28).

---

Key Disclosure Gaps

To fully model the financial impact, institutional investors require the following parameters, which were not reported in the corporate action disclosures:

• Existing Share Capital Base: The total number of outstanding equity shares of Aye Finance is not reported, leaving the percentage dilution (12.63 lakh shares divided by existing shares) uncalculable.
• Option Fair Value: The fair value per option (incorporating stock price volatility, risk-free rate, expected life, and dividend yield) is not disclosed.
• Vesting Tranches: The specific allocation of the 12.63 lakh options across the 1-to-4-year vesting schedule is not reported, preventing a precise calculation of the FY27 amortization charge.

The total ESOP pool size under the 2024 scheme and its specific grant magnitude relative to total outstanding equity are not separately disclosed in the provided filings or news context. Consequently, a precise ESOP-to-equity ratio for Aye Finance cannot be calculated, nor can it be benchmarked against comparable MSME-focused NBFCs.

Disclosure Status

• Aye Finance: While the company is in the process of an IPO ^[3], the specific size of the 2024 ESOP pool and the number of shares granted under this scheme are not explicitly stated in the available financial filings or the Draft Red Herring Prospectus (DRHP) addendum ^[3], ^[4].
• Peer Benchmarking: Comparable MSME-focused NBFCs (such as Five Star Business Finance, SBFC Finance, and others mentioned in the company's peer set ^[3]) do not have their aggregate ESOP-to-equity ratios disclosed in the provided structured KPI data or news summaries.

Financial Context

As of Q4 FY26, Aye Finance reported an Equity Share Capital of Rs 48.90 Crores and Total Equity of Rs 2,532.7 Crores ^[5], ^[6]. Without the specific number of options authorized or granted under the 2024 scheme, we cannot determine the potential dilution impact or the ratio of the ESOP pool to the total outstanding equity.

Limits

• Data Gap: The absence of the ESOP pool size in the provided documentation prevents a quantitative comparison.
• Comparability: Even if the pool size were available, industry-wide ESOP-to-equity ratios for MSME-focused NBFCs are not standardized in the provided context, making a direct peer-based benchmark speculative.